Clinical Trial Update: Safety & Tolerability of the IRay System in Subjects With Exudative Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) [Phase 1]

View source ↗

Summary

This Phase 1 trial update reports on the safety and tolerability of the IRay System in subjects with exudative choroidal neovascularization secondary to age-rel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Wet Age-related Macular Degeneration

Snippet

Sponsor: Oraya Therapeutics, Inc. | Conditions: Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration | Phase 1 | Status: UNKNOWN